Radium-223 delivers high-energy radiation to osseous metastases. Its effect on the immune system is known. We observed a decrease in the mean frequency of programmed cell death protein 1-expressing cytotoxic T cells after 1 treatment of radium-223 in patients with prostate cancer. Further investigation is warranted to define the clinical significance of this finding and to elucidate the immunologic aspect of how radium-223 mediates its anti-tumor activity. Background: Radium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8þ T cell subsets in patients with prostate cancer is unknown. Patients and Methods: Fifteen men with metastatic prostate cancer with clinical indication for Ra223 without any autoimmune or immune deficiency conditions were enrolled. Patients received a course of Ra223 50 kBq/kg. Concurrent use of prednisone 10 mg a day was allowed. Peripheral blood samples were collected before and 3 to 4 weeks after the first dose of Ra223 50 kBq/kg. Peripheral blood mononuclear cells were purified and analyzed for the phenotypic and functional characteristics of CD8 þ T cells using flow cytometry.
Introduction
Radium-223 (Ra223) is an alpha-radiation emitting radioisotope approved in treatment of metastatic castration resistant prostate cancer (mCRPC). A phase III randomized, placebo-controlled study demonstrated that Ra223 improves survival in men with mCRPC by 3.6 months (median, 14.9 months vs. 11.3 months, in Ra223 treated group vs. placebo group, respectively) with a hazard ratio of death, 0.70 (95% confidence interval, 0.58-0.83; P < .001), and delays time to first skeletal event by 5.8 months (hazard ratio, 0.66; 95% confidence interval, 0.52-0.83; P ¼ .00037) with a favorable safety profile.
1,2 Ra223, as a calcium mimetic, localizes to osteoblastic metastases of prostate cancer, and emits alpha particles, leaving irreparable double-stranded DNA damage and eventual cell death. In addition to its conventional cytotoxic effect via damaging DNA, radiation induces immunogenic cell death by affecting various compartments of the immune system. 3, 4 Preclinical studies have shown that radiation upregulates the expression of antigenpresenting MHC molecules and affects cytokine production and various subpopulations of immune cells as well as stromal cells. [5] [6] [7] [8] A beta particle-emitting radioisotope, Samarium-153-EDTMP (Sm-153), has been shown to induce immunogenic modulation by altering the phenotype of tumor cells such that they are more susceptible to T-cell mediated killing. 7 A randomized phase II study of Sm-153 in combination with a prostate-specific antigen-targeted vaccine, versus Sm-153 alone, showed a trend toward improvement in the 4-month progression-free rate (23.8% vs. 11.1%; P ¼ .27), and an improvement in median progression-free survival of 3.7 months versus 1.7 months (P ¼ .046). 9 In addition, several other clinical trials incorporated external beam radiation therapy, in combination with an immune-based therapy to capitalize on its immune modulating effects. [10] [11] [12] [13] The effect of Ra223 on human immune systems is unknown. We hypothesized that Ra223 would affect the CD8þ T cell and its subsets in patients with metastatic prostate cancer. We investigated the immunologic effect of Ra223 in patients with mCRPC by examining the phenotypic and functional characteristics of CD8 þ T cells that include the expression of co-stimulatory, co-inhibitory molecules, and cytokines.
Patients and Methods

Patient Population
A total of 15 men with castration-resistant prostate cancer with osseous metastases with clinical indication for Ra223 were enrolled. Patients with active autoimmune disease requiring therapy, or with known immunodeficiency syndrome were excluded. Patients who had been on low-dose corticosteroids ( 10 mg prednisone daily) were allowed. Patients received a course of Ra223 50 kBq/kg intravenously every 4 weeks as a standard practice. Table 1 shows clinical characteristics of the study subjects. Research blood was collected at 2 time points: (1) before and (2) 3 to 4 weeks after the first dose of Ra223 50 kBq/kg.
Purification and Stimulation of Peripheral Blood Mononuclear Cells (PBMCs)
PBMCs were isolated from heparinized peripheral venous blood using Ficoll-Hypaque gradient (GE Healthcare, Piscataway, NJ). PBMCs were washed with phosphate buffered saline (PBS) and resuspended in RPMI 1640 media supplemented with 10% fetal calf serum and 1% glutamine/penicillin/streptomycin. Cells were stimulated for 4 hours with PBS (control) or PMA (50 ng/ml; Sigma, St. Louis, MO) and ionomycin (1 mg/ml; Sigma) in the presence of Golgiplug (BD Biosciences, San Jose, CA) in a tissue culture incubator at 37 C as previously done.
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Flow Cytometry
Fresh PBMCs were stained with anti-CD3-APC-Cy7, CD8-APC, CD45RA-PE-Cy5, CCR7-PE-Cy7, PD-1-Pacific Blue, IL-7Ra-FITC, CD27-PE, CD28-PE, CTLA4-PE, CX3CR1-PE antibodies, or isotype control (all from BioLegend, San Diego, CA). PBMCs that had been stimulated with PMA/ionomycin were stained with anti-CD3-APC-Cy7, CD8-APC, CD45RA-PE-Cy5, and CCR7-PE-Cy7 antibodies followed by fixation, permeabilization (Cytofix/Cytoperm Kit, BD Biosciences), and staining with anti-IFNg-PE, TNF-a-FITC, or IL-13-PE antibodies (BioLegend).
14 Stained cells were analyzed on an LSRII flow cytometer (BD Biosciences). Collected data were analyzed using FlowJo software (Tree Star, Ashland, OR).
Statistical Analysis
Statistical analysis was done using the GraphPad Prism 6 (GraphPad Software, La Jolla, CA). P values less than .05 were considered statistically significant.
Results
The Frequency of PD-1-Expressing Effector Memory (EM) CD8 þ T Cells Decreased in Patients With mCRPC After a Treatment of Ra223
To determine the possible effect of Ra223 on the expression of co-stimulatory and -inhibitory molecules by CD8 þ T cells in patients with mCRPC, we analyzed the expression CD27, CD28, PD-1, and CTLA-4 on different subsets of CD8 þ T cells in these patients before and after Ra223 administration. Based on the expression of the T cell receptor co-receptor CD45RA and lymphoid tissue homing chemokine receptor CCR7, we identified naive (CD45RA
þ T cells in peripheral blood ( Figure 1A ). The overall frequency of lymphocytes, total CD8 þ T cells, naive, CM, and EM CD8 þ T cells did not change after Ra223 treatment (Table 2) . Most naive and CM CD8 þ T cells expressed CD27 and CD28 but not PD-1 (data not shown). In EM CD8 þ T cells, some cells expressed CD27, CD28, and/or PD-1 ( Figure 1B ). The frequency of PD-1 A Decrease in the Frequency of PD-1 Expression Was Also Observed Among IL-7Ra high EM CD8 þ T Cells
The cytokine IL-7 and its receptor IL-7 receptor alpha (IL-7Ra) play a major role in the generation and maintenance of memory T 
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Effect of Radium-223 on Immune System cells by promoting cell survival. 17 We previously showed the presence of 2 distinct cells expressing high and low levels of IL-7Ra in human EM CD8 þ T cells. 18 A recent study reported that tumorspecific effector CD8 þ T cells with the capacity to establish immunological memory in humans after adoptive transfer are marked by IL-7Ra. 19 Thus, we analyzed the frequency of IL- 
Ra223 Treatment Does Not Alter the Frequency of CD8
þ T Cells Expressing IFN-g, TNF-a, and IL-13
T helper (Th) 1 cytokines, such as IFN-g and TNF-a, can promote anti-tumor immunity by activating T cells, natural killer cells, and monocytes, whereas Th2 cytokines such as IL-13 can be associated with cancer progression. [20] [21] [22] The expression of cytokines by CD8 þ T cells were also examined in patients with mCRPC before and after Ra223 treatment using flow cytometry ( Figure 3A ).
The frequency of CD8 þ T cells expressing IFN-g, TNF-a, and IL-13 were similar in blood samples collected before and after Ra223 ( Figure 3B ).
Discussion
To the best of our knowledge, this is the first study to investigate the effect of Ra223 treatment on CD8 þ T cells in patients with mCPRC. Although there was no significant change observed in overall frequencies of CD8 þ T cell or their major subsets, it appears 14.6% post-treatment; P ¼ .020). The decrease in PD-1 expression was also observed in IL-7Ra high EM CD8 þ T cells (P < .001). The expression of other immune checkpoint molecules including CD27, CD28, and CTLA4 remained unchanged. Also, the expression of cytokines, including IFN-g, TNF-a, and IL-13, remained unchanged. It is unclear if this selective decrease in the frequency of PD-1-expressing CD8 þ EM cells is because of apoptosis of PD-1-expressing T cells, down-regulation of PD-1 receptor on these T cells, or other mechanisms. Our study does not provide an explanation for any of these hypothetical mechanisms. Nevertheless, it generates hypotheses that are subject to further investigation. PD-1 is a transmembrane glycoprotein, a member of the CD28/ CTLA-4 immunoglobulin family and an inhibitory co-receptor expressed on T cells. 23 PD-L1. [29] [30] [31] [32] A study is warranted to investigate if the Ra223 is, in fact, associated with upregulation of PD-L1 expression in the tumor microenvironment of osteoblastic metastases. Another speculation is that Ra223, by undefined mechanisms, causes relative expansion of resting T cells that are PD-1-negative, following the exhaustion and apoptosis of PD-1-expressing CD8 þ EM T cells without further expansion of activated T cells. This speculation is supported by our observation that there was no significant increase in production of proinflammatory cytokines, such as IFN-g, and TNF-a. However, this hypothesis is not so wellgrounded because contrary evidence exists to suggest that radiation often increases antigen exposure and presentation to T cells by inducing the release of tumor antigens and upregulation of major histocompatibility complex. 6, 8, 33 Nonetheless, this remains a hypothesis subject for further investigation. There are several limitations in interpreting our data. The first is lack of data at multiple data points post Ra223 treatment. The study was originally planned to obtain the blood samples after 3 and after 6 treatments. However, most of the patients had early termination of Ra223 treatment owing to progressive disease. Therefore, the blood samples at later time points could not be collected as planned. Our patients were generally well-advanced in their disease status with median prior therapy of 3, 62% of patients with prior chemotherapy, 100% of patients with an Eastern Cooperative Oncology Group performance status of 2. Our observation may be related to the poor prognostic factors of our study patients. Second, the lack of control data from normal peripheral blood limits the interpretation of our data. Our data are the change of these immune subsets from before to after the treatment. The normal variance of these subsets in normal peripheral blood is unknown. Therefore, the immunologic significance of these changes remains to be a subject of further investigations. Third, our data analysis was exploratory from a small sample size. Albeit, it was interesting to observe that there was a mean decrease in a subset of PD-1-expressing T cells following a Ra223 therapy.
A phase I/II study of an anti-PD-L1 antibody, atezolizumab, in combination with Ra223 is ongoing, to study the safety and optimal sequencing of these therapies (NCT02814669). In this study, patients will be randomized to start Ra223 either before, after, or concurrent with the first dose of atezolizumab. A phase II study of Ra223 with or without anti-PD-1 antibody, pembrolizumab, is also enrolling patients (NCT03093428). Both trials require a pair of tumor biopsies to interrogate the immune tumor microenvironment on Ra223-treated tumors. Among others, these biopsies will examine whether or not Ra223 upregulates PD-L1 expression. Further, a randomized phase II study of sipuleucel-T with or without Ra223 in men with mCRPC (NCT02463799) is ongoing. This study will examine if Ra223 makes a difference in mounting peripheral immune responses to sipuleucel-T.
Additionally, there is an ongoing clinical trial of glycosylated recombinant human interleukin-7 subcutaneous injection after a course of sipuleucel-T therapy for metastatic prostate cancer as an immune booster (NCT01881867). The cytokine IL-7 and its receptor IL-7 receptor alpha (IL-7Ra) play a critical role in the generation and maintenance of memory T cells. 17 Our data indicate that both IL-7Ra high and IL-7Ra low cells in EM CD8 þ T cells were detected in PBMCs of the patients and their frequencies were not affected after the Ra223 treatment. The aforementioned study will test if the memory response to sipuleucel-T would be maintained with IL-7 subcutaneous injection.
Conclusion
A Ra223 treatment was associated with a decrease in frequency of PD-1-expressing CD8 þ EM T cells.
Clinical Practice Points
Ra223 is an alpha radiation-emitting radioisotope that results in irreparable DNA damage in osteoblastic metastases of prostate cancer and cell death. 
